AR, androgen receptor, 367

N. diseases: 854; N. variants: 163
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE PCa is reliant on androgen receptor (AR); as such, first-line therapy for metastatic PCa entails suppression of AR signaling. 29530944 2019
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE Androgen receptor signaling is critical for prostate adenocarcinoma, even after androgen deprivation therapy. 29605661 2018
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE Hence the aim of the current study was to investigate whether TXA<sub>2</sub>/TP-induced PRK activation can mimic and/or enhance AR-mediated cellular responses in the model androgen-responsive prostate adenocarcinoma LNCaP cell line. 28108419 2017
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. 27180064 2017
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 AlteredExpression disease BEFREE A relationship between the Gleason score and AR expression was also determined in cases of prostatic adenocarcinoma. 27072221 2016
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 AlteredExpression disease BEFREE Compounds 2 and 5 were proven to be androgen receptor antagonists due to their binding activities for androgen receptors (IC50 280 and 160 μM, respectively) and the inhibitory activity of androgen-induced expression of prostate-specific antigen (PSA) mRNA in LNCaP (prostate adenocarcinoma) cells (IC50 20 and 18 μM, respectively). 23402539 2013
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE Therefore, we have identified potential cells of origin and a molecular target for prostatic SCNC that are very different from those of conventional adenocarcinoma, which explains SCNC's distinct biology and the clinical observation that it does not respond to hormonal therapy targeting androgen receptor signaling, which produces short-term therapeutic effects in nearly all patients with prostatic adenocarcinoma. 22389383 2012
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 AlteredExpression disease BEFREE LNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma. 21432867 2011
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Therapeutic disease RGD Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. 18439064 2009
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 AlteredExpression disease BEFREE In situ hybridization and immunocytochemistry were used to examine AR expression in prostatic needle core biopsies of benign, high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma. 19670238 2009
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE We used immortalized human prostate epithelial cells (iPrECs), androgen receptor-overexpressing iPrECs (AR-iPrEC), and human prostate adenocarcinoma LNCaP cells that stably overexpressed FASN for cell proliferation assays, soft agar assays, and tests of tumor formation in immunodeficient mice. 19318631 2009
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 AlteredExpression disease BEFREE The present study is to address if quercetin may affect Sp1's action on AR transactivation activity in human prostate adenocarcinoma cell lines, LNCaP and PC-3. 15661808 2005
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 Biomarker disease BEFREE Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4. 12837460 2003
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 GeneticVariation disease BEFREE The data presented here show that this simple AR assay is convenient for the routine detection of mutant ARs in PCa and is also suitable to evaluate the antagonist activities of anti-androgen molecules. 12534363 2003
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 AlteredExpression disease BEFREE Our study revealed the average AR expression in the prostate adenocarcinoma was 52.2 +/- 27.1%, which was significantly lower than that in the adjacent non-tumorous prostate tissue (68.3 +/- 18.3% in average) (P < 0.001). 12445232 2002
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 CausalMutation disease CGI
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate
0.600 GenomicAlterations disease CGI